Full year revenues $2.09M (down 10.7% from 2015) and a net operating loss of $1.4M. Net loss was $2.1M.
Only $5.8K in cash on balance sheet at end of year. They will have been borrowing more cash in 1Q/17.
OS stands at 14.97B, up nearly 2.4B shares from the end of 3Q/16. With the higher stock price in 1Q/17 higher due to the FDA news, the pace of increase should have slowed some in the quarter that ended today.
For the fourth quarter, revenues were $399.5K, down 40% from 4Q/15.